arginine has been researched along with Cholangiocellular Carcinoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bates, DO; Boonsri, B; Duangdara, J; Grabowska, AM; Janvilisri, T; Kangsamaksin, T; Supradit, K; Suriyonplengsaeng, C; Thitiphatphuvanon, T; Tohtong, R; Wongprasert, K; Yacqub-Usman, K | 1 |
| Amartey, JO; Babaei-Jadidi, R; Bates, DO; Egbuniwe, IU; Erdelyi, V; Evans, HR; Jackson, AM; Morris, JC; Patel, PM; Pratoomthai, B; Wahid, M; Yacqub-Usman, K | 1 |
| Chen, J; Fu, X; Gu, S; Han, X; He, J; He, W; Qiu, Y; Yan, M; Yan, X; Zhou, Q | 1 |
| Chenvidhya, D; Fujii, T; Honjo, S; Jedpiyawongse, A; Matharit, M; Miwa, M; Ohshima, K; Ohta, E; Sripa, B; Srivatanakul, P; Tanaka, H; Tanaka, M; Viwatthanasittiphong, C; You, G; Zeng, L | 1 |
| Imai, Y; Ishikawa, T; Nakatsuru, Y; Oda, H | 1 |
5 other study(ies) available for arginine and Cholangiocellular Carcinoma
| Article | Year |
|---|---|
Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis.
Topics: Arginine; Cholangiocarcinoma; Humans; Neovascularization, Pathologic; Protein Isoforms; Protein Serine-Threonine Kinases; RNA, Messenger; Serine; Serine-Arginine Splicing Factors; Vascular Endothelial Growth Factor A | 2022 |
Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T ce
Topics: Alternative Splicing; Arginine; B7-H1 Antigen; Cholangiocarcinoma; Humans; Immunotherapy; Interleukin-2; Leukocytes, Mononuclear; Phosphorylation; Programmed Cell Death 1 Receptor; Protein Isoforms; Protein Serine-Threonine Kinases; RNA Splicing Factors; Serine; Serine-Arginine Splicing Factors; T-Cell Exhaustion | 2023 |
Higher content of microcystin-leucine-arginine promotes the survival of intrahepatic cholangiocarcinoma cells via regulating SET resulting in the poorer prognosis of patients.
Topics: Arginine; Bile Duct Neoplasms; Cell Proliferation; Cholangiocarcinoma; Disease-Free Survival; DNA-Binding Proteins; Female; Histone Chaperones; Humans; Leucine; Male; Microcystins; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; RNA Interference; RNA, Messenger; RNA, Small Interfering | 2021 |
Combined effects of polymorphisms of DNA-repair protein genes and metabolic enzyme genes on the risk of cholangiocarcinoma.
Topics: Alanine; Arginine; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cysteine; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; Genotype; Glutamine; Glutathione Transferase; Histidine; Humans; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Risk Assessment; Risk Factors; Serine; Valine; X-ray Repair Cross Complementing Protein 1 | 2013 |
A polymorphism at codon 160 of human O6-methylguanine-DNA methyltransferase gene in young patients with adult type cancers and functional assay.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arginine; Base Sequence; Carcinoma, Hepatocellular; Child; Cholangiocarcinoma; Codon; Cysteine; DNA Primers; Exons; Female; Glycine; Humans; Kidney; Liver Neoplasms; Male; Methyltransferases; Middle Aged; Molecular Sequence Data; O(6)-Methylguanine-DNA Methyltransferase; Point Mutation; Polymerase Chain Reaction; Polymorphism, Genetic; Reference Values; Spleen; Stomach Neoplasms | 1995 |